10.55 (-%)
As of Dec 03, 2024
Source:
Igm Biosciences, Inc is a clinical-stage biotechnology company pioneering the development of IgM antibodies for the treatment of cancer, autoimmune and inflammatory diseases, and infectious diseases. IgM antibodies have inherent properties that we believe may enable them to bind more strongly to targets on the surface of cells than comparable IgG antibodies.
Country | United States |
Headquarters | mountain view, california |
Phone Number | (650) 965-7873 |
Industry | manufacturing |
CEO | Fred Schwarzer |
Website | www.igmbio.com |